Unresectable Triple-negative Breast Cancer
📧 Sign up to get email alerts when something new happens for Unresectable Triple-negative Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer [Phase 1]
Phase 1 clinical-trial update exploring adding ZEN003694 (ZEN-3694) and pembrolizumab to nab-paclitaxel for patients with locally advanced o…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer [Phase 1]
A Phase 1 trial is evaluating the addition of ASTX727 (cedazuridine/decitabine) to paclitaxel and pembrolizumab for metastatic or unresectab…
-
CLINICAL_TRIALS trial_result · 2025-07-28Clinical Trial Update: Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer [Phase 1, Phase 2]
Clinical trial update reports on the combination of copanlisib and eribulin in metastatic triple-negative breast cancer in Phase 1/2, with r…
-
CLINICAL_TRIALS withdrawal · 2025-01-29Clinical Trial Update: Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer [Phase 2]
Phase 2 trial evaluating a dendritic cell-based treatment combined with immunotherapy for metastatic or unresectable triple-negative breast …